KNOWLEDGE / Publication / POST
November 3, 2023

Using aggregated site features computed with the MPsQ to allow a better monitoring of sites in clinical trials


The MPsQ is an assessment characterizing the profile of the subjects participating to a Randomized Controlled Trial (RCT) to predict their behaviors in the study (placebo response, adherence, …). This analysis aimed to determine whether individual responses collected through the MPsQ could serve for characterizing clinical sites in RCTs. The objective is to enhance study data comprehension by profiling clinical site.

Design :

Historical data from five diverse RCTs across varying medical indications (Chronic Pain, Degenerative Disease, and Ophthalmology) were employed. Analysis was restricted to clinical sites with a minimum of 10 subjects, resulting in a dataset comprising 1164 subjects distributed across 56 clinical sites. For this first analysis, two site scores were aggregated using the subjects answers to MPsQ—namely, subjects’ expectations of improvement and interaction with clinical sites.

Results :

The analysis showed significant correlations between subject scores and the scores of their associated sites: 36% (95% CI: [0.31, 0.40]) for Expectations and 20% (95% CI: [0.13, 0.27]) for Interactions. Leveraging the 2 aggregated site scores allowed also to characterize other site characteristics with, e.g., the explanation of approximately 31% of the variance in drop-out rates across individual sites.

Conclusion :

This analysis underscores the potential of MPsQ features to effectively profile clinical sites in RCTs. These profiles, reflective of intrinsic site attributes, demonstrably impact subject behaviors. Moreover, these profiles can explain disparities in subject behaviors across different sites. Characterizing the sites could improve the post-hoc data understanding and the conduct of studies through relevant feedback.

Scientific Poster
Arthur Ooghe, Samuel Branders, Jérôme Paul, Dominique Demolle, Alvaro Pereira
November 9, 2023
CNS Summit 2023

Related content


Correcting For The Individual Patient Regression To The Mean Effect

Often, the primary endpoint of RCTs is defined as a change from baseline of a continuous outcome. In…

Type: Scientific Poster
Authors: Samuel Branders, PhD; Guillaume Bernard, PhD; Alvaro Pereira, PhD
Conference: American Society for Clinical Pharmacology and Therapeutics
Read More

Do Environmental Parameters Influence The Prediction Of The Placebo Response?

This proof-of-concept study on peripheral neuropathic pain patients investigates the potential influence of the investigator on the placebo…

Read More

Bayesian Modeling Of The Placebo Response In Neuropathic Pain

In analgesia randomized clinical trials (RCTs), the magnitude and the variability of the placebo response have a negative…

Type: Scientific Poster
Authors: Samuel Branders, PhD; Alvaro Pereira, PhD; Frederic Clermont, PhD; Chantal Gossuin; Dominique Demolle, PhD
Conference: Promoting Statistical Insight Conference
Read More

The next frontier in clinical research & patient management

We’re proud to be leading the charge into the next era of drug development.
Cognivia helps clinical trials reduce data variability, empower decision-making, and accelerate the launch of new therapies.
Tell us about your clinical trial below and we’ll be in touch.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.